
Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating zzso which are seldom zzso suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease zzso and are limited by imperfect zzso and zzso zzso The promise of an era of zzso therapies renders urgent the search for reliable measures of zzso zzso have the potential to enhance several aspects of both therapeutic trials and clinical zzso zzso measures of cerebral volume can provide a surrogate for zzso loss and several techniques have been applied to zzso disease zzso aid diagnosis, and enable monitoring of progression in a variety of zzso disorders, including Parkinson's disease, zzso with zzso bodies, multiple system zzso progressive zzso zzso and zzso zzso We review the approaches to, and findings revealed by, serial zzso zzso in these zzso 

